Print

Sven Andréasson new President & CEO of Active Biotech

1998-12-16

The Board of Directors today appointed Sven Andréasson as new President & CEO of Active Biotech, effective February 1, 1999.

Sven Andréasson is 46 years, graduate from the Stockholm School of Economics, IMEDE and INSEAD. Sven Andréasson comes from Pharmacia & Upjohn, where he last served as President at the French subsidiary. France is one of the five most important markets for the group, with a turnover amounting to 2,5 billions SEK and 1100 employees.

Since Sven Andréasson began his working career, he has worked within the pharmaceutical industry with responsibilities for functions such as research, manufacturing, finance & administration and above all marketing and business development. An important milestone was the creation of the BioPharma division within KabiVitrum, with responsibility for development and launch of a biosynthetic growth hormone, a low molecular weight heparin as well as the plasma products.

Resigning President & CEO Bo Håkansson will continue to work within the company and will succeed Hugo Thelin as chairman of the board. Hugo Thelin will be appointed vice chairman of the board.

"By appointing Sven Andréasson as President & CEO of Active Biotech AB the company will get access to an executive with long and wide experience from the biotechnology and pharmaceutical industry. Sven Andréasson has gained his experience through achievements in both Sweden and internationally. At the same time the company's resigning President & CEO and major owner Bo Håkansson will get the opportunity to concentrate on the long-term and strategic issues facing the company." says Active Biotech AB's Chairman of the board Hugo Thelin.

Lund December 16, 1998

Board of Directors

Questions will be answered by:
Bo Håkansson
Tel. +46 46 19 20 88
E-mail: bo.hakansson@activebiotech.com

Sven Andréasson
Tel. +33 1 30 64 34 02
E-mail: sven.andreasson@eu.pnu.com

Active Biotech is a biotechnology company with a broad and in-depth product portfolio and with sustainable liquid funds. The Group's operations are based on know-how in immunology. Some 185 researchers in Lund, Solna and Cambridge develop vaccines for tourist diarrhoea, cholera, polio, streptococci and streptococci infections, and conduct research into new drugs for treatment of multiple sclerosis, rheumatism, asthma and cancer.

Active Biotech AB
Box 724
SE-220 07 LUND
Sweden
pdf



Back